Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01947140 · ClinicalTrials.gov registry record · Phase 1
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
A Phase 1 study of Multiple Myeloma and Lymphoma, sponsored by Jennifer Amengual.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 3
- Study locations
NCT01947140: Completed Phase 1 study of Multiple Myeloma and Lymphoma, sponsored by Jennifer Amengual.
NCT01947140 is a Phase 1 study of Multiple Myeloma and Lymphoma that has completed, run by Jennifer Amengual. The registered enrollment target is 57 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01947140, a Phase 1 study of Multiple Myeloma and Lymphoma, has completed, sponsored by Jennifer Amengual.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest. If the combination is determined to be safe, the study will continue accrual patients with peripheral T-Cell lymphoma (PTCL).
Primary Outcome
For Phase I
Conditions Studied
Interventions
- DRUG Pralatrexate
- DRUG Romidepsin
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New York
- Columbia University Irving Medical Center - New York
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-09-09 |
| Est. Completion | 2022-09-01 |
| Phase | Phase 1 |
What the finished NCT01947140 record still lists
NCT01947140 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower).
The record links to 5 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Pralatrexate is the first listed.
NCT01947140 reports a single indexed study location in Massachusetts, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01947140 about?
NCT01947140 is a clinical study titled "Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies". This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest. If the combination is determined to be safe, the study will continue accrual patients with periph...
What is the current status of trial NCT01947140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2013-09-09. Estimated completion is 2022-09-01.
What conditions does trial NCT01947140 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Lymphoid Malignancies.
What interventions are being tested in trial NCT01947140?
The interventions under investigation include: Pralatrexate (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT01947140?
This trial is sponsored by Jennifer Amengual, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01947140 being conducted?
This trial has 3 study locations across Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01947140's enrollment target sits among peer trials
57 235th of 438 higher than 201 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI